BProtected Pedia D-Vite Disease Interactions
There are 5 disease interactions with BProtected Pedia D-Vite (cholecalciferol).
Vitamin D analogs (applies to BProtected Pedia D-Vite) arrhythmia
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides. Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias. Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.
Vitamin D analogs (applies to BProtected Pedia D-Vite) electrolyte imbalance
Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance
Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or renal systems or other soft tissue calcifications. A solubility product (Serum Calcium X Phosphate) should not exceed 70. Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.
Vitamin D analogs (applies to BProtected Pedia D-Vite) hypercalcemia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome
Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.
Vitamin D analogs (applies to BProtected Pedia D-Vite) renal dysfunction
Major Potential Hazard, High plausibility.
Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation. Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.
Vitamin D analogs (applies to BProtected Pedia D-Vite) hepatobiliary dysfunction
Moderate Potential Hazard, High plausibility. Applicable conditions: Liver Disease, Biliary Obstruction
Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs. Metabolites of vitamin D analogs are primarily excreted in bile and feces. Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation. Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs. Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.
Switch to professional interaction data
BProtected Pedia D-Vite drug interactions
There are 91 drug interactions with BProtected Pedia D-Vite (cholecalciferol).
BProtected Pedia D-Vite alcohol/food interactions
There is 1 alcohol/food interaction with BProtected Pedia D-Vite (cholecalciferol).
More about BProtected Pedia D-Vite (cholecalciferol)
- Check interactions
- Compare alternatives
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: vitamins
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.